Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Increased all-cause mortality with psychotropic medication in Parkinson's disease and controls: A national register-based study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Practical management of adverse events related to apomorphine therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Understanding the role of the Parkinson's disease nurse specialist in the delivery of apomorphine therpy

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease - Clinical practice recommendations

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. YKL-40 in cerebrospinal fluid in Huntington's disease - A role in pathology or a nonspecific response to inflammation?

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Assessment of diurnal melatonin, cortisol, activity, and sleep-wake cycle in patients with and without diabetic retinopathy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Disturbed sleep in cluster headache is not the result of transient processes associated with the cluster period

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Neuroimaging markers of global cognition in early Alzheimer's disease: A magnetic resonance imaging-electroencephalography study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

AIM: Use of medication and polypharmacy is common as the population ages and its disease burden increases. We evaluated the association of antidepressants, benzodiazepines, antipsychotics and combinations of psychotropic drugs with all-cause mortality in patients with Parkinson's disease (PD) and a matched group without PD.

METHOD: We identified 5861 PD patients and 31,395 control subjects matched by age, gender and marital status, and obtained register data on medication use and vital status between 1997 and 2007.

RESULTS: All-cause mortality was significantly higher with the use of most groups of psychotropic medication in PD patients and controls. Hazard ratios were as follows for the medication types: selective serotonin reuptake inhibitors or serotonin-noradrenalin reuptake inhibitors, PD HR = 1.19, 95% CI = 1.04-1.36; Control HR = 1.77, 95% CI = 1.64-1.91; benzodiazepines, PD HR = 1.17, 95% CI = 0.99-1.38; Control HR = 1.39, 95% CI = 1.29-1.51; benzodiazepine-like drugs, PD HR = 1.33, 95% CI = 1.11-1.59; Control HR = 1.27, 95% CI = 1.18-1.37; first-generation antipsychotics, PD HR = 1.89, 95% CI = 1.42-2.53; Control HR = 2.12, 95% CI = 1.82-2.47; second-generation antipsychotics, PD HR = 1.46, 95% CI = 1.20-1.76; Control HR = 2.00, 95% CI 1.66-2.43; and combinations of these drugs compared with non-medicated PD patients and controls. Discontinuation of medication was associated with decreased mortality in both groups.

CONCLUSIONS: The use of psychotropic medication in the elderly is associated with increased mortality, independent of concurrent neurodegeneration due to PD. Confounding by indication may partly explain the higher hazard ratios in medicated controls compared with medicated PD patients. Our findings indicate that neurodegeneration should not be a separate contraindication per se for the use of psychotropic drug in patients with PD, but its use should be based on careful clinical evaluation and follow-up.

Original languageEnglish
JournalParkinsonism & related disorders
Volume20
Issue number11
Pages (from-to)124-8
Number of pages5
ISSN1353-8020
DOIs
Publication statusPublished - 1 Aug 2014

ID: 44565077